The white paper 'Shifting the Biomanufacturing Paradigm: Intensifying Upstream Processes' is now available to download
The first commercial monoclonal antibody (mAb) was approved in 1986 and today, the global market is large and growing. Reports estimate the size of the market to be approximately $100 billion with expectations of it growing to more than $130 billion by 2023, a robust compound annual growth rate of more than 5.5%.1,2
The demand for mAbs and other antibody-based biologics continues to be fuelled by a number of factors including:
Click here to download the white paper and learn more.